6:00 PM
 | 
Oct 04, 2012
 |  BC Extra  |  Company News

EMA to review masitinib for GIST

AB Science S.A. (Euronext:AB) said EMA accepted for review an MAA for masitinib to treat Gleevec-resistant gastrointestinal stromal tumors (GIST). The MAA is...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >